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Attention-deficit/hyperactivity disorder (ADHD) is a prevalent neurodevelopmental disorder, often
associated with other psychiatric comorbidities, functional impairments, and poor long-term outcomes.
The objective of this selected review is to describe current advances and challenges in the diagnosis
and treatment of ADHD. The disorder is associated with neurobiological underpinnings and is highly
heterogeneous in various aspects, such as symptom profiles, cognitive impairments, and
neurobiological and genetic features. The efficacy and safety of short-term pharmacological
treatments across the life cycle is well studied, but further research investigating long-term treatment,
impact of treatment in preschoolers, and non-pharmacological interventions is needed. Future
research is also needed to better characterize the neurodevelopmental pathways of the disorder,
linking clinical and neurobiological information, less investigated populations, and new interventions.
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Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a neu-
rodevelopmental disorder that affects approximately 5%
of children and adolescents worldwide.1 Although symp-
toms decline with age (65% of the affected individuals
present partial remission), only 15% of children with
ADHD show full remission in early adulthood, character-
izing a chronic disorder.2,3 Symptoms include age-
inappropriate inattentiveness, hyperactivity, and impul-
sivity.4 The disorder is highly burdensome, determining
significant functional impairments, such as social and
family life problems, low educational attainment and
school dropout, low self-esteem, impairment in emotional
development, occupational problems, and divorce.4
Furthermore, it is associated with other psychiatric
comorbidities, especially oppositional defiant disorder,
anxiety disorder and learning disabilities; it also predicts a
diversity of negative outcomes, such as future conduct
disorder, antisocial behavior, anxiety and mood disor-
ders, substance abuse, and also physical injuries, traffic
accidents, premature pregnancy, sexual transmitted
diseases, among others.5,6
ADHD is a cause of significant economic costs to
society. A recent systematic literature review suggests
that the annual incremental costs of the disorder in the
U.S. are at least US$ 143 billion.7 Despite that, the
disorder is still poorly recognized and treated, and there is
a lack of public policies developed to address this
condition. In the U.S., less than two-thirds of adolescents
with ADHD had ever received some kind of treatment.8
This situation is even more dramatic in low- and middle-
income countries. For example, in a community sample of
two cities in Brazil that ascertained approximately 10,000
children, 43% of children with ADHD had been previously
referred to mental health services, but only 23% had
access to some kind of treatment (A Graeff-Martins,
personal communication).
The etiology of ADHD has not been completely
elucidated.9 Studies have identified a robust genetic
contribution to the disorder, with pooled heritability rate of
76%.10 Current data indicate that multiple common
genetic variants of small effect - including genes of
dopaminergic, noradrenergic, serotoninergic and other
systems - and possible rare variants, are implicated in the
etiology of ADHD.9 Environmental variables are also
known to play a role in the disease etiology. Low birth
weight, prematurity, and intra-utero exposure to tobacco
are among the environmental factors most strongly linked
to the development of the disorder.9 It is likely that
multiple etiological pathways involving different genetic
variants and exposures in complex interaction underlie
specific neuropsychological characteristics and clinical
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symptoms of the disorder (Figure 1). The complexity of
the pathways leading to ADHD results in remarkable
heterogeneity in many aspects of the disorder, which
might be limiting the ability to elucidate the disease
etiology.11
Various characteristics of ADHD have been summar-
ized by previous systematic reviews.1,3,9,12,13 The objec-
tive of this selected review of the literature is to describe
current advances and challenges in the conceptualiza-
tion, diagnosis, and treatment of the disorder.
Diagnosis
ADHD as a neurodevelopmental disorder
Accumulating evidence supports the notion that ADHD is
better understood as a neurodevelopmental disorder
characterized by a maturational delay. In the last years,
the frequent description of an immature child or adoles-
cent made by parents and teachers has found support in
neuroimaging studies.14 A National Institute of Mental
Health longitudinal study provided unique developmental
insights into the neurobiology of ADHD. In a landmark
report published in 2007, Shaw et al.15 studied the cortical
thickness of 223 patients who had ADHD and 223
typically developing controls. Their results indicated that,
rather than a deviation from typical development, ADHD
is characterized by a marked delay in reaching peak
thickness in many regions and particularly in the
prefrontal cortex (median age 10.5 and 7.5 years for the
ADHD and control groups, respectively).15 More recently,
the same group extended this finding, suggesting a mirror
phenomenon in terms of measures of cortical surface
area: among children with ADHD, the median age by
which 50% of right prefrontal cortical vertices attained
peak area was 14.6 years - in comparison to 12.7 years in
the healthy control group.16
The developmental aspect of ADHD must be taken into
account when characterizing clinical presentation and
elaborating new diagnostic criteria. The diagnosis of
ADHD is established clinically, based on criteria defined
by diagnostic classification systems such as the DSM and
ICD. Similar to other psychiatric conditions, there is no
ancillary test with sufficient predictive power for the
diagnosis of ADHD. Core features of the disorder are
developmentally inappropriate symptoms of inattention,
hyperactivity, and impulsivity (Table 1). Notwithstanding
the emphasis regarding the need for a developmental
perspective in the assessment of ADHD, limited
evidence-based data is available on specific manifesta-
tions of the disorder at each period of life.
The validity of ADHD among preschoolers has been an
area of particular controversy in the literature. Although
there is increasing evidence that ADHD constitutes a
valid diagnosis before the age of 6,17 challenges in the
diagnostic procedures include, for example, the impossi-
bility of observation in multiple settings for those children
not attending preschool - and subsequent lack of
information about pervasiveness. Several studies have
shown that currently available criteria reliably identify
ADHD in children as young as 2 years old and that these
individuals have clinically significant impairment across
all relationships and settings.18
Research has also documented the validity of ADHD
diagnosis among older adolescents and young adults.
Despite the observed age-dependent decline in ADHD
symptoms, a substantial proportion of individuals con-
tinue to present clinically relevant symptoms as they
enter into adulthood. Reduction of hyperactive/impulsive
symptoms is more significant than that of inattentive
symptoms (remission in 70 vs. 40% of individuals,
respectively).19 Among the challenges in characterizing
ADHD in older individuals, there is the inappropriateness
of the description of symptoms (especially hyperactivity/
Figure 1 Schematic representation of ADHD pathophysiology. The figure shows the path to ADHD phenotype and the various
levels where heterogeneity may occur. Genetic (G1-Gn) and environmental factors (E1-En), and complex gene-environment
interactions (GxE) lead to various neurobiological changes, which in turn lead to different neuropsychological impairments and
symptom profiles. ADHD = attention-deficit/hyperactivity disorder
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impulsivity symptoms) to capture developmental specific
clinical manifestation, and difficulties in assessing retro-
spectively the presence of symptoms in childhood.20 In
addition, the clinical picture in adults might be specifically
characterized by symptoms related to executive dysfunc-
tions and emotional impulsivity. More importantly, adults
might present substantial impairment even with lower
number of symptoms in any of the two dimensions
(inattention and/or hyperactivity/impulsivity). Thus, a
lower symptom threshold for the diagnosis in adults was
proposed for the new version of the DSM - DSM-5.20
Other challenges in ADHD diagnosis
In addition to frequent developmentally inappropriate
symptoms (at least 6/9 in at least one of the dimensions),
there are other requisites for the diagnosis of ADHD
according to the DSM-IV-TR. One of the most fragile
criteria for the diagnosis of ADHD is the requirement of
symptoms causing impairment before the age of 7 years
(criterion B). This criterion has been retained in DSM
editions despite the lack of empirical support, and a
systematic review of the literature found 31 studies
questioning its validity, especially to older individuals,
for whom there can be problems in terms of retrospective
recall.21 Applying this evidence-based approach, the
forthcoming DSM-5 will reformulate the criterion, expand-
ing the maximum age at onset to 12 years. This reaffirms
ADHD as a disorder of childhood onset, both minimizing
false negatives and causing minimal increase in pro-
spectively assessed prevalence rates.22
The requirement of some impairment from the symp-
toms in two or more settings (criterion C) is intended to
avoid including situational-specific problems (e.g., only at
home). Interestingly, the low concordance between
parental and teacher reports (even when focusing on
symptoms at school) suggests that, to capture perva-
siveness, information should be gathered with both
sources.23 The diagnosis of ADHD is currently excluded
in the presence of disorders such as schizophrenia
(criterion E). Another change announced for the DSM-5
is the removal of the impossibility of diagnosing ADHD
and autism spectrum disorders, as there is sufficient
evidence to justify the comorbid diagnosis.24
Data converge to confirm that ADHD is a disorder with
developmental features that are associated with neurobio-
logical underpinnings. Future research - preferably using
longitudinal designs - is needed to better characterize the
neurodevelopmental pathways of the disorder, linking both
clinical and neurobiological information.
ADHD as a heterogeneous disorder
It is noteworthy that children with ADHD vary significantly
from each other. ADHD, as other psychiatric disorders, is
a highly heterogeneous disorder in respect to various
Table 1 DSM-IV-TR diagnostic criteria for ADHD
A. Either 1) or 2):
Inattention
1. Six (or more) of the following symptoms of inattention have persisted for at least 6 months to a degree that is maladaptive and
inconsistent with developmental level:
a) Often fails to give close attention to details or makes careless mistakes in schoolwork, work, or other activities
b) Often has difficulty sustaining attention in tasks or play activities
c) Often does not seem to listen when spoken to directly
d) Often does not follow through on instructions and fails to finish schoolwork, chores, or duties in the workplace (not due to
oppositional behavior or failure to understand instructions)
e) Often has difficulty organizing tasks and activities
f) Often avoids, dislikes, or is reluctant to engage in tasks that require sustained mental effort (such as schoolwork or homework)
g) Often loses things necessary for tasks or activities (e.g., toys, school assignments, pencils, books, or tools)
h) Is often easily distracted by extraneous stimuli
i) Is often forgetful in daily activities
2. Six (or more) of the following symptoms of hyperactivity-impulsivity have persisted for at least 6 months to a degree that is maladaptive
and inconsistent with developmental level:
Hyperactivity
a) Often fidgets with hands or feet or squirms in seat
b) Often leaves seat in classroom or in other situations in which remaining seated is expected
c) Often runs about or climbs excessively in situations in which it is inappropriate (in adolescents or adults, may be limited to
subjective feelings of restlessness)
d) Often has difficulty playing or engaging in leisure activities quietly
e) Is often on the go or often acts as if driven by a motor
f) Often talks excessively
Impulsivity
g) Often blurts out answers before questions have been completed
h) Often has difficulty awaiting turn
i) Often interrupts or intrudes on others (e.g., butts into conversations or games)
B. Some hyperactive-impulsive or inattentive symptoms that caused impairment were present before age 7 years
C. Some impairment from the symptoms is present in two or more settings (e.g., at school [or work] and at home)
D. There must be clear evidence of clinically significant impairment in social, academic, or occupational functioning
E. The symptoms do not occur exclusively during the course of a pervasive developmental disorder, schizophrenia, or other psychotic
disorder and are not better accounted for by another mental disorder (e.g., mood disorder, anxiety disorder, dissociative disorder, or a
personality disorder)
ADHD = attention-deficit/hyperactivity disorder.
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aspects, such as symptom profiles, neuropsychological
profiles, and neurobiological and genetic features
(Figure 1).
One aspect of ADHD heterogeneity is related to its
clinical presentation. Diagnosis of mental disorders,
according to diagnostic manuals, may be assigned from
different combinations of criteria listed under the same
disorder.25 In the case of ADHD, six symptoms are
required for an individual to meet diagnostic criteria.
Because the criteria are subdivided into symptom
domains (inattention and hyperactivity/impulsivity), it is
possible that two individuals diagnosed with ADHD do not
have the same group of symptoms. The classification of
ADHD diagnosis into types (predominantly inattentive,
hyperactive-impulsive, and combined types) is an attempt
to deal with the heterogeneity of clinical presentations.
Even so, two individuals with identical ADHD subtypes
might be similar in as few as three symptoms. In a
community sample of 189 individuals with ADHD, a total
of 173 combinations of symptomatic profiles were found.
Furthermore, it was detected a median agreement
between symptoms of 0.61, with 30% of the sample
showing an agreement lower than half of the symptoms
(G Salum, personal communication). This indicates the
limited ability of the current clinical diagnostic criteria in
defining homogeneous populations, which may be one
reason why the field has not yet been successful in
finding biological markers of ADHD.11 Conversely, a
recent comprehensive meta-analyses did not detect
significant differences in several assessed areas compar-
ing subjects with different ADHD types (main compar-
isons between predominantly inattentive and combined
types), arguing that these phenotype differences might
not be so relevant.26 Based on these findings and on the
low developmental stability of ADHD types, the ADHD
working group for the DSM-5 recently proposed the
downgrade of the types to current presentation.
Another facet of ADHD heterogeneity is neuropsycholo-
gical heterogeneity. ADHD has been shown to be asso-
ciated with various neuropsychological impairments.
Studies have found that, on average, individuals with
ADHD, compared to controls, have worse performance in
executive functions, such as: inhibition, working memory,
memory span, processing speed, arousal, temporal infor-
mation processing, response variability; and have also
impairments in motivational processes.27-33 However, the
findings of neuropsychological impairments are only of
moderate effect sizes and not all individuals with the
disorder have these dysfunctions.27,34 Sonuga-Barke et
al.35 evaluated three neuropsychological domains: inhibitory
control, delay aversion, and temporal processing, and found
that ADHD children had poorer performance on all domains.
However, only 71%of the individuals displayed some deficit,
and 70% of those showed just one dysfunction.35 The
results suggest that the three domains are independent
components of ADHD and support a triple pathway model
for ADHD. Fair et al.36 recently conducted another study
illustrating the neuropsychological heterogeneity in ADHD.
They identified distinct neuropsychological subgroups
within ADHD children and also within typically developing
children.36 The findings support that ADHD heterogeneity,
as well as heterogeneity in typical population, must be
considered when trying to elucidate ADHD etiology.
Taking into account heterogeneity in neuropsychologi-
cal and symptom profiles, theoretical models of ADHD
have proposed that dysfunctions in multiple pathways
may be involved in the disorder, leading to specific
impairments.35,37,38 Nigg & Casey37 proposed that ADHD
may arise from: a) dysfunctions in brain cognitive control
systems, b) over-reactivity in nucleus accumbens circuit,
or c) under-reactivity in amygdalar-frontal circuit; each
leading to related but distinct etiological phenotypes,
which are, respectively: a) primary inattentive, disorga-
nized, and ineffective behaviors; b) impulsive, overactive
behaviors; and c) impulsive conduct problems, antisoci-
ality. Sonuga-Barke, who had previously proposed a dual
pathway model (i.e. delay aversion and executive
dysfunction pathways),38,39 recently suggested that three
dissociable pathways might be involved in ADHD
etiology.35 The neuroimaging literature has shown that
ADHD is related to alterations in several brain systems,
including systems involved in attention, cognitive control,
emotional, sensorimotor, and reward processes.12,40-47.
Most of those studies have focused on single process
hypotheses and have not addressed the multiple path-
ways model. Further evaluation of how distinct neurop-
sychological or behavioral phenotypes relate to
differential neural pathways may be particularly relevant
to elucidate heterogeneity of ADHD neural substrates.
ADHD heterogeneity is also evident at the genetic level.
Genome-wide association studies are inconclusive, but
candidate genes studies have found evidence for the
association of various genes with elevated risk for
ADHD.48,49 This may suggest that each genetic marker
accounts for only a small proportion of heritability, indicating
that ADHD arises from a complex interaction of genetic
susceptibility and environmental conditions.50,51 Numerous
possibilities of gene combinations added to countless
possible interactions with environmental conditions generate
pronounced heterogeneity from the genetic point of view.
Therefore, there is compelling evidence that the
heterogeneity of ADHD might be one reason for the
diversity of findings and lack of replication. It has become
crucial that research concerning all aspects of ADHD,
such as neurobiology, diagnosis, and treatment, take
heterogeneity into account and employ new approaches
to deal with this issue.
Treatment
Efficacy of interventions
The recommendations for ADHD treatment indicate
multimodal approaches including pharmacotherapy and
psychosocial interventions as the most effective. First-
line medications for the treatment of ADHD are stimulants
(methylphenidate, mixed amphetamine salts, and amphe-
tamine derivatives - lisdexamfetamine and dextroamphe-
tamine). Second-line medications are atomoxetine,
tricyclic antidepressants, bupropion, and alpha-agonists.
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Meta-analyses and systematic reviews show moderate
to large effect sizes of stimulants in short-term reduction
of symptoms.52-56 Most of the studies comparing short
and long-acting methylphenidate compounds found no
significant differences in effect sizes.55,57 However, a
meta-analysis looking at medications for adults with
ADHD found that the clinical response for short-acting
stimulants was greater than for long-acting stimulants.58
Non-stimulants are considered second-line medica-
tions in cases of treatment failure, intolerance or contra-
indication to stimulants and may be an option in specific
cases of comorbidity.59 There is good level of evidence
provided by meta-analysis of efficacy for atomoxe-
tine.57,60,61 Extended-release clonidine62-64 and
extended-release guanfacine65,66 are also efficacious
options for the treatment of ADHD, alone or in combina-
tion with stimulants. Other pharmacologic alternatives
evaluated for the treatment of ADHD are modafinil,
bupropion,57 and tricyclic antidepressants,67 but all of
them have showed weaker evidence of efficacy.
Behavioral therapy for ADHD aims to modify the
physical and social environment in order to modify
behavior. For preschoolers, parent training is the recom-
mended behavioral intervention. This modality of treat-
ment aims to help parents stop inefficacious patterns of
interaction with their child by reinforcing child’s prosocial
behavior and to extinguish unwanted behaviors.68,69
A recent meta-analysis examined 40 studies addressing
the efficacy of behavior parent training for parents of
children of ADHD.68 A moderate effect size was found
regarding the improvement of child behavior and parenting
behavior (both measured objectively), and parental per-
ception of parenting. However, these results were
observed only immediately after treatment. In a long term
(up to 3 years), results remained significant, but with lower
magnitude (small effect size). Improvement was more
limited for children with associated oppositional defiant
disorder or other behavioral problems. Another meta-
analysis summarized randomized controlled trials that
assessed the efficacy of the following non-pharmacologi-
cal treatment modalities: restricted elimination diets,
artificial food color exclusions, free fatty acid supplementa-
tion, cognitive training, neurofeedback, and behavioral
interventions.13 Given the restriction to high-quality trials,
six to 15 studies were included for each modality. Authors
conducted two sets of analysis: the first considered ADHD
assessment by raters closest to the therapeutic setting,
and the second considered only probably blinded assess-
ment of the outcomes by the individual studies. According
to the first set of analysis, all six modalities of intervention
produced significant effects. According to the second set of
analysis, only free fatty acid supplementation and artificial
food color exclusion produced significant effects, and the
effects of the other four modalities were non-significant.13
Long-term efficacy and effectiveness
The short-term efficacy of ADHD treatment is well
documented, but fewer studies, with variable results, have
evaluated long-term efficacy and effectiveness. Poor
adherence and difficulties in retention during follow-up
are probably some of the reasons for this gap in the
literature. However, since ADHD is a lifelong condition, it is
fundamental to determine the long-term outcomes of the
different treatment modalities. The Multimodal Treatment
Study of Children with ADHD (MTA)70 is a large trial that
compared four treatment modalities (behavioral interven-
tion, medication, combined treatment, or routine commu-
nity) in respect to several outcomes during 14 months
(controlled phase) and the subsequent 8 years (open
phase). Results indicated that, after 14 months of follow-
up, medication alone or combined with behavior interven-
tion had better results on improving ADHDand oppositional
defiant disorder symptoms, compared to behavior inter-
vention and community care.70 Combined behavioral
intervention and medication was no better than medication
management, but allowed the use of lower stimulant
doses. Secondary analysis looked at rates of success
defined by a cutoff on the SNAP-IV score at the end of the
treatment.71 Results from the secondary analysis found
increased success rates for combined treatment and
medicationmanagement and confirmed the initial results.71
An 8-year follow-up of MTA children, however, did not
find differences between the four treatment groups, and
children with ADHD combined subtype showed poorer
functioning than non-ADHD children, despite the improved
outcomes compared with baseline.72 These results sug-
gest that an initial period of randomly assigned treatment
does not change the disorder trajectory. Conclusions from
these results are widely discussed. It is possible that: a)
treatment was not effective in the long-term; b) medication
and behavioral interventions are equally effective; or c)
community care is effective in the long-term, and intensive
medication management or intensive behavioral therapy
improve its effectiveness, but the benefit weakens once
the controlled treatment stops.73 It is also argued that the
naturalistic design of the follow-up after 1 year (children
returned to community care) may have influenced the
results.74 In conclusion, long-term controlled studies are
needed in order to better understand the continuing effects
of different modalities of treatment on symptoms and
functioning of individuals with ADHD, and also to explore
potential moderators of long-term outcomes.
A recent systematic review summarized findings from
studies assessing long-term outcomes of treatment vs.
non-treatment of ADHD.75 It was found that ADHD
individuals left untreated had poorer long-term outcomes
compared to treated individuals in nine major categories,
but treatment did not result in normalization. Benefits were
more prominent in driving, obesity, self-esteem, social
function, academic, and drug use/addictive behavior out-
comes. Although the superiority of specific treatment
modalities still needs to be further studied, it appears that
in general ADHD treatment improves long-term outcomes.
However, the field still demands studies to clarify the
association between shot-term and long-term effects.
Functional outcomes
Another challenge for ADHD treatment is determining
functional outcomes of treatment (e.g., academic and
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occupational outcomes). Although few studies have
investigated this topic, there is evidence of positive
impact on specific outcomes. In regard to academic
outcomes, Hechtman et al.76 found improvement of
school performance and homework behaviors in children
with ADHD treated with medication associated or not with
other treatment modalities (psychosocial treatment or
academic intervention). A recent review by Prasad et al.77
examined children’s on-task behavior and academic
performance and found that drug treatment improved
children’s time spent on task and amount of schoolwork
they completed. Scheffler et al.78 also found that
medicated children with ADHD had higher mathematics
and reading scores. In regard to criminality, during
periods under treatment with medication, individuals with
ADHD presented lower criminality rates (measured as
any conviction for a crime) compared to non-medicated
periods.79 Brook et al.80 recently studied the relationship
between ADHD in adolescence and several outcomes in
adulthood, and found that adolescents with ADHD are
more likely to have impaired physical and mental health,
antisocial personality disorder, impaired work perfor-
mance, and high financial stress in adulthood. Raman
et al.81 documented that the treatment with stimulants
decrease the risk for injuries in children (see slide
attached).
In regard to substance use, there is no evidence that
medication treatment increases the chance of developing
dependence.75 Results are conflicting with respect to the
protective potential of treatment. Biederman et al.82 found
a reduced risk for substance use disorders in medicated
individuals with ADHD after 4 years. This was consistent
with an earlier meta-analysis.83 However, a 36-month
follow-up of the MTA study84 and a 10-year follow-up
study of a clinical sample85 found no association between
ADHD treatment and rates of substance use. Additional
studies assessing large samples and following up
participants into adolescence and/or adulthood are
necessary to determine whether treatment has a protec-
tive effect on substance use rates and development of
dependence.
Treatment of preschool children
Treatment plan for preschoolers must take into account
the intensity of symptoms, pervasiveness, but also the
velocity and intensity of changes that occur in the brain
during this phase. There is scarce data about efficacy and
safety of stimulants for this age group, and most of the
studies are restricted to methylphenidate.86 The largest
randomized controlled trial conducted for this age period
is the Preschool ADHD Treatment Study (PATS),87 which
included 165 children aged 3 to 5.5 years in the
medication phase. The inclusion criteria for this study
were very rigorous: only children with moderate to severe
ADHD-related impairment for at least 9 months were
included; it was also required a level below 55 on the
Children’s Global Assessment of Functioning Scale; and
a cross-site panel of clinicians had to agree about the
inclusion and exclusion criteria for the enrollment of each
participant. Furthermore, all participants underwent a
Parent Training phase and only participants with con-
tinued impairment were allowed to begin medication.88
Therefore, children who participated in the study,
especially in the medication phase, exhibited severe
ADHD, which may explain the high rates of comorbidities
they presented.87 The mean optimal daily dose of
methylphenidate (0.760.4 mg/kg/day) was lower than
the dose recommended for school age children.87 There
were significant reductions in ADHD symptoms, but the
effect sizes (0.4-0.8) were smaller than the ones found for
school age children. Despite the relative good tolerability
of methylphenidate, adverse effects were more fre-
quent.86 The most common described adverse effects
are decreased appetite, stomachache, sleep difficulties,
social withdrawal, lethargy, dysphoria, crying, whining,
and irritability.
In respect to non-stimulant treatment, there is a
randomized controlled trial of atomoxetine in 5- and 6-
year old children with ADHD, demonstrating significant
improvement in symptom scores compared to placebo.89
One-third to one-fourth of subjects reported adverse
events, which included weight loss, decreased appetite,
sedation, and gastrointestinal discomfort, but they were
not related to treatment discontinuation.
Group-based parent training is a psychosocial inter-
vention tested for preschool ADHD. Sonuga-Barke et
al.90 performed a controlled trial with 3-year-old children
with ADHD, who were randomized to parent training,
parent counseling and support, or a waiting list group.
They found that parent training significantly improved
ADHD symptoms (in clinical and direct observation
measures) and mother’s sense of well-being, and 53%
of children in the parent training group met criteria for
recovery by the end of the trial. The beneficial effects of
parent training were still present 15 weeks after treat-
ment. Another study by Jones et al.91 evaluated the
effectiveness of parent training for reducing ADHD
symptoms in preschool children with ADHD symptoms
(not a formal ADHD diagnosis) and conduct problems,
and found similar results. Parent training was associated
with significant greater reduction in ADHD symptoms, and
52% of children in the parent training group presented
symptom scores below clinical threshold by the end of the
intervention (against 21% for the waiting list control
group). However, Barkley et al.92 found no effect of
parent training on ADHD symptoms in kindergarteners,
which may be explained by the low adherence to
treatment, inclusion of children with symptom scores
above a cutoff in a dimensional rating scale but without a
formal diagnosis of ADHD, lack of impaired functioning
indicated by parents and teachers, and the training format
(delivered in a didactic format). Evidence for the effec-
tiveness of parent treatment for improving ADHD symp-
toms in preschoolers is still limited and additional
controlled trials with children formally diagnosed with
ADHD are needed.86
Clinical guidelines indicate psychosocial intervention as
first-line treatment for preschool children with ADHD. The
guidelines by the American Academy of Pediatrics,17 the
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Preschool Psychopharmacology Working Group,93 and
the NICE Guideline94 recommend specifically group-
based parent training, reserving methylphenidate for the
more impaired cases or for those children who do not
benefit significantly from behavior treatment.17,86,93,94
Future studies should assess the efficacy and safety of
other stimulants, of stimulants compared to parent
training, and their short- and long-term effects in this
age range, as well as long-term effects of psychosocial
interventions.
Treatment of adults
Literature about the treatment of adults with ADHD is not
as extensive as for school-age children, but a consider-
able amount of data is already available. Pooled
estimation from meta-analysis shows that stimulants
decrease adults’ ADHD symptoms in short-term bases
with a medium to large effect size. When stimulants as a
group are compared to placebo, the effect size found is
0.67.95 Other meta-analyses found effect sizes of 0.9 for
methylphenidate,96 0.73 for mixed amphetamine salts,97
0.8 for lisdexamfetamine (extracted from a single
study),97 and 0.6 for dextroamphetamine.97 Non-stimu-
lants, when considered as a group, seem to be inferior to
stimulants, with pooled effect size of 0.3953 and 0.59.95
Meta-analytic data also showed bupropion to be superior
to placebo but less effective than stimulants.58,98,99
Other non-stimulants were assessed by clinical trials
with no meta-analysis yet available. The superiority of
atomoxetine to placebo has been demonstrated in a
pooled post-hoc estimation combining data from six
double-blind trials100 and also by additional more recent
clinical trials.101-103 Modafinil was not superior to placebo
in a well conducted clinical trial that included more than
300 patients.104 Limited evidence is available for alpha-2-
agonists for adults.105 A randomized, double blind,
placebo-controlled trial compared the efficacy of guanfa-
cine with dextroamphetamine for the treatment of ADHD
in adults.106 The study found that guanfacine was similar
to dextroamphetamine in reducing ADHD symptoms,
compared to placebo, but only guanfacine improved
performance on the Color-Word subtest of Stroop,
indicating an enhancement of focused attention by
guanfacine. A nicotinic agonist has also been studied
for treating adult ADHD.107 A randomized, double-
blinded, placebo-controlled trial, with a crossover design,
selected adults with ADHD to receive placebo and ABT-
894, a4b2 (a subtype of neuronal nicotinic receptors)
agonist, or atomoxetine.107 ABT-894 4 mg twice-daily
was comparable to atomoxetine and superior to placebo
in reducing ADHD symptoms, but additional studies, with
larger sample sizes, greater power, and a parallel design
(to avoid results susceptibility to carryover effects) are
need to better evaluate the safety and efficacy of this
drug.
Psychosocial interventions for adults do not appear to
be effective as sole treatment, but evidence shows that
they may be effective as adjunctive treatment to
psychopharmacological therapy for individuals with resi-
dual symptoms.108 The best evidence comes from a trial
conducted by Safren et al.109 The study enrolled 86
adults with ADHD who were already being prescribed
medication and randomized them to cognitive behavioral
therapy or relaxation with attentional support. Cognitive
behavioral therapy was associated with greater improve-
ment in ADHD symptoms - with improved scores in the
ADHD-rating scale, Clinical Global Impression severity,
and self-report ADHD scale -, and the benefits were
maintained after 12 months of follow-up.
As children and adolescents mature, further studies
should be conducted to assess the continuous efficacy of
treatment in adulthood, as well as for newly diagnosed
individuals. Additionally, new compounds with already
available preliminary data should be further tested.
Adverse events
Pharmacological treatment of ADHD may be associated
with a range of adverse effects. Adverse effects are
mostly mild and/or transitory, and although serious
adverse events are rare, they are a subject of concern
and debates.110 The European ADHD Guidelines Group
(EAGG) recently reviewed the most common adverse
effects and proposed recommendations for clinical
management.111 The most common adverse effects
associated with stimulants are reduction of appetite,
sleep disturbance, tics, seizures, and psychotic symp-
toms. The impact of stimulants on growth and its
cardiovascular risks prompted significant concerns
among clinicians and authorities and debate in the media.
Growth delay is likely caused by inappropriate nutrition
due to loss of appetite.112 A review found deficit in height
associated with stimulant use, but also found that the
deficit tends to attenuate over time.112 Some studies also
found that growth delay is dose-dependent and can be
compensated within 2 years after discontinuing treat-
ment.112 Recommendations from the EAGG to manage
growth deficit involve: managing loss of appetite (high-
caloric snacks, medication after meals, late evening
meals); monitoring appetite, weight, height and body
mass index regularly; alternative options (i.e., medication
holidays, pausing medication on weekends); and refer-
ring to a growth specialist if necessary.111 Table 2
displays clinical recommendations for managing appetite
loss and growth delay in children treated with ADHD
medications.
Because stimulants can potentially increase blood
pressure and heart rate, a lot has been speculated about
the risk of serious cardiac events of stimulant users.
Nevertheless, there is evidence that stimulants are not
associated with changes in electrocardiographic
parameters or with serious cardiovascular events (mean-
ing sudden cardiac death, acute myocardial infarction
and stroke).113-115 Habel et al.115 conducted a retro-
spective cohort study, evaluating electronic health
records of 443,198 adults, of whom 150,359 were users
of ADHD medications (methylphenidate, amphetamine,
or atomoxetine) at baseline. The study investigated
cardiovascular events such as myocardial infarction,
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sudden cardiac death, and stroke. No evidence was
found for the association of current use with increased
risk of cardiovascular events, compared with nonuse or
remote use (risk ratio of any cardiovascular event for
current use = 1.03; 95% confidence interval [95%CI]
0.86-1.24). Similar results were found in another retro-
spective cohort study that analyzed automated data from
health plans from more than 1,200,000 children and
young adults.114 The results showed that current use of
ADHD drugs was not associated with increased risk for
cardiovascular events (hazard ratio of cardiovascular
events for current use = 0.75, 95%CI 0.32-1.85), but the
upper limit of 1.85 for the wide confidence interval found
requires attention. It is recommended to investigate
history of heart disease and family history of sudden
death under the age of 40, and to refer the patient to a
complete cardiologic evaluation before commencing
treatment if either of those is present.111 Heart rate and
blood pressure should be assessed at baseline and
monitored regularly during the course of treatment, but
there is no evidence to support routine electrocardiogram
before prescribing ADHD medication.111 Table 3 shows
recommendations regarding monitoring and managing
cardiovascular risk in children and adolescents treated
with ADHD medications.
The presence of adverse events should be evaluated
and managed carefully when prescribing ADHD medica-
tions but, although all effort should be made to avoid
exposing patients to unnecessary harm, it is important to
adequately treat individuals who need treatment. It is also
fundamental to perform a detailed assessment of
pretreatment conditions and family history that increases
risk for severe adverse events, avoiding negative events
that can be anticipated.
Final considerations
There has been a growing investment in research on
ADHD over the years. As a result, accumulating evidence
supports the validity of the diagnosis. Current data
indicate that ADHD is the outcome of deviant develop-
mental processes and complex interactions between
genetic variants and environmental exposures. There is
no identifiable risk factor at the present moment that is
either sufficient or necessary for the occurrence of the
disorder. Therefore, it is hypothesized that different
combinations of risk factors can lead to ADHD. The
underlying etiological heterogeneity is likely to result in
heterogeneity in the clinical presentation; countless
different combinations of cognitive impairments and
behavioral manifestations can be identified in individuals
classified under the diagnosis of ADHD.
ADHD is frequently associated with important negative
outcomes during development and in adulthood.
Therefore, early detection and intervention are funda-
mental for reducing the burden of the disorder for the
individuals, families, and the society. The efficacy and
safety of pharmacological agents has been extensively
demonstrated for the short-term treatment of the disorder.
Less data is available for the long-term treatment and for
non-pharmacological interventions. Evidence for the
treatment of preschoolers and adults with ADHD is also
less abundant. In the near future, long-term follow-up
studies, evaluation of less studied populations, and
development and assessment of new interventions are
expected to contribute to further advance the knowledge
about ADHD.
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Table 2 Management of loss of appetite and growth delay during treatment with ADHD medications111
1. Monitor weight, height, BMI, and appetite regularly. Use standardized national charts for monitoring height, weight, and BMI.
2. To reduce appetite loss: give medication after meals, use high-calorific snacks and late evening meals.
3. Alternative for managing appetite loss and/or growth delay:
a. Discontinue medication during weekends or drug holidays may be useful, but the risk-benefit balance should be carefully considered.
b. Switch medication to another class or formulation.
4. Refer child to an endocrinologist or growth specialist if weight and/or height values are below critical thresholds.
BMI = body mass index.
Table 3 Management of cardiovascular risk during treatment of children and adolescents with ADHD medications111,113
1. Before starting ADHD medication:
a. Conduct detailed interview to investigate personal and familial cardiovascular risk factors. If there is history of risk factors, refer to the
child/adolescent’s primary care physician or cardiologist.
b. Measure baseline BP and heart rate. If readings are above normal for age/gender/height (o 95th percentile), refer to the primary care
physician for further evaluation.
c. Routine ECG is not mandatory.
2. During treatment with ADHD medication:
a. Repeat BP and heart rate measures at each visit. If readings are above normal for age/gender/height (o 95th percentile), refer to the
primary care physician or indicate drug reduction or drug holiday.
b. Monitor change in personal or familial history of cardiovascular risk and refer to the primary care physician, if necessary.
ADHD = attention-deficit/hyperactivity disorder; BP = blood pressure; ECG = electrocardiogram.
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